Press release
Mesothelioma Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight | Novartis, Oncovir, Sumitomo Pharma, Bayer, Epizyme, Sanofi, AstraZeneca, Shionogi, Eli Lilly, GSK, Incyte Corporation,
Mesothelioma Pipeline
Key Takeaways from the Mesothelioma Pipeline Report
• DelveInsight's Mesothelioma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Mesothelioma treatment.
• The leading companies working in the Mesothelioma Market include Kissei Pharmaceutical Co., Ltd., Novartis Pharmaceuticals, Oncovir, Inc., Sumitomo Pharma Oncology, Bayer, Trizell Ltd, Hutchison Medipharma Limited, Targovax, Polaris Group, Epizyme, Inc., Sanofi, AstraZeneca, Ascentage Pharma Group Inc., Shionogi, Eli Lilly and Company, Incyte Corporation, GlaxoSmithKline, Constellation Pharmaceuticals, Tmunity Therapeutics, Xencor Inc., NGM Biopharmaceuticals Inc., Inhibrx, Inc., VM Oncology, LLC, SOTIO Biotech AG, Atara Biotherapeutics, and others.
• Promising Mesothelioma Pipeline Therapies in the various stages of development include Nivolumab, Ipilimumab, Pemetrexed, MTG201, THOR-707, Pembrolizumab, IAG933, Volrustomig, Carboplatin, and others.
• December 2023: PrECOG LLC announced a study of Phase 3 clinical trials for Durvalumab. The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with PM.
• December 2023: AstraZeneca announced a study of Phase 3 clinical trials for Volrustomig, Pemetrexed, Carboplatin and Cisplatin. This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.
Request a sample and discover the recent advances in Mesothelioma Treatment Drugs @ Mesothelioma Pipeline Outlook Report- https://www.delveinsight.com/report-store/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
In the Mesothelioma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Mesothelioma NDA approvals (if any), and product development activities comprising the technology, Mesothelioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Mesothelioma Overview
Mesothelioma is a cancer caused by asbestos. It most commonly occurs in the linings of the lungs or the abdomen. The average life expectancy is 18 - 31 months after diagnosis, but prognosis may improve with treatment. Symptoms can include chest pain, shortness of breath and general fatigue.
Find out more about Mesothelioma Therapeutics Assessment @ Mesothelioma Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Mesothelioma Emerging Drugs Profile
• MesoPher: Amphera
• Durvalumab: AstraZeneca
Mesothelioma Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the Mesothelioma therapies. The Mesothelioma companies which have their Mesothelioma drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.
DelveInsight's Mesothelioma pipeline report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
Mesothelioma Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Learn more about the emerging Mesothelioma Pipeline Therapies @ Mesothelioma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Mesothelioma Pipeline Report
• Coverage- Global
• Mesothelioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Mesothelioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Mesothelioma Companies- Kissei Pharmaceutical Co., Ltd., Novartis Pharmaceuticals, Oncovir, Inc., Sumitomo Pharma Oncology, Bayer, Trizell Ltd, Hutchison Medipharma Limited, Targovax, Polaris Group, Epizyme, Inc., Sanofi, AstraZeneca, Ascentage Pharma Group Inc., Shionogi, Eli Lilly and Company, Incyte Corporation, GlaxoSmithKline, Constellation Pharmaceuticals, Tmunity Therapeutics, Xencor Inc., NGM Biopharmaceuticals Inc., Inhibrx, Inc., VM Oncology, LLC, SOTIO Biotech AG, Atara Biotherapeutics, and others.
• Mesothelioma Pipeline Therapies- Nivolumab, Ipilimumab, Pemetrexed, MTG201, THOR-707, Pembrolizumab, IAG933, Volrustomig, Carboplatin, and others.
Dive deep into rich insights for new drugs for Mesothelioma Treatment, Visit @ Mesothelioma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Mesothelioma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Mesothelioma - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Mesothelioma Collaboration Deals
9. Late Stage Products (Phase III)
10. Durvalumab: AstraZeneca
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. TRC102: TRACON Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. SG001: CSPC ZhongQi Pharmaceutical Technology
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Mesothelioma Key Companies
23. Mesothelioma Key Products
24. Mesothelioma- Unmet Needs
25. Mesothelioma- Market Drivers and Barriers
26. Mesothelioma- Future Perspectives and Conclusion
27. Mesothelioma Analyst Views
28. Mesothelioma Key Companies
29. Appendix
For further information on the Mesothelioma Pipeline therapeutics, reach out to Mesothelioma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Ambulatory Arrhythmia Monitoring Devices Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Choroidal Neovascularization Market: https://www.delveinsight.com/report-store/choroidal-neovascularization-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Cardiopulmonary Bypass Equipment Market: https://www.delveinsight.com/report-store/cardiopulmonary-bypass-equipment-market
• Chemotherapy Induced Anemia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Clbp Market: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/infographics/pemphigus-vulgaris-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Calciphylaxis Market: https://www.delveinsight.com/report-store/calciphylaxis-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Inflammtory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Cutaneous T-cell Lymphoma Market: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market
Contact Info:
Ankit Nigam
Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mesothelioma Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight | Novartis, Oncovir, Sumitomo Pharma, Bayer, Epizyme, Sanofi, AstraZeneca, Shionogi, Eli Lilly, GSK, Incyte Corporation, here
News-ID: 3472502 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Mesothelioma
Mesothelioma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Mesothelioma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Mesothelioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Mesothelioma Pipeline Report
• DelveInsight's Mesothelioma pipeline report depicts a…
Mesothelioma Resource Centre Introduced the All Legal Rights and Options Platfor …
Mesothelioma Resource Centre announced the platform for all legal rights and options of Asbestos & Mesothelioma. It is the legal and health resources center for all sufferers of mesothelioma cancer, a cancer almost always caused by exposure to asbestos.
Generally, a mesothelioma victim must immediately seek redress once diagnosed with the cancer because if the disease has been established to be work-related and the responsible company is identified, a mesothelioma…
New Mesothelioma Treatment Technique Developed
Extrapleural pneumonectomy, a surgical procedure that removes mesothelioma cancer from the lining of the lung, has been reported to be an effective new mesothelioma treatment technique. The technique was developed by Dr. Sugarbaker, the co-leader of the Brigham Biomedical Research Institute's Cancer Research Center, Chief of the Institute's Division of Thoracic Surgery and a Professor of Oncologic Surgery at Harvard Medical School.
The surgical technique was applied on a mesothelioma patient…
Mesothelioma Cancer: Possible Treatment Option
An experiment carried out in Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and the Medical University Vienna has tested the effectiveness of a genetically modified virus to treat mesothelioma in animals. The virus is known as Newcastle Disease Virus (NDV). Animals with mesothelioma administered with multiple doses of NDV responded better than those that received a single dose.
The use of a genetically engineered virus to disrupt the function…
Veteran Passed Away from Mesothelioma Cancer
It has been reported that a U.S. Army veteran passed away at the age of 64 from the asbestos cancer, malignant mesothelioma. He retired from the U.S. Army Corps of Engineers after 25 years of service. Prior to his military career, he worked at a steel company. It is likely that his mesothelioma was caused by asbestos exposure that he encountered at the steel company and during military service.
Malignant mesothelioma…
Weitz & Luxenberg Mesothelioma Lawyers win $1.28 Million Settlement in Mesotheli …
Weitz & Luxenberg mesothelioma lawyers recently secured a $1.28 million settlement for a 77-year-old former carpenter suffering from the asbestos cancer, mesothelioma. Prior to this settlement, Weitz & Luxenberg obtained $842,000 from another defendant.
The former carpenter is the father of six children and devoted his 30-year career to beautifying such New York City landmarks as Yankee Stadium and the Empire State Building. He was diagnosed with mesothelioma in…
